OrbiMed, Wellington backers of Chinese biotech Gracell

Wellington Management Company and Morningside Ventures joined healthcare investment specialists OrbiMed and Vivo Capital to lead a $100 million Series C round for Gracell Biotechnologies.
"We are very pleased to expand our investor base with support from a high caliber consortium," said Dr. William Wei Cao, founder, chairman, and CEO of Gracell, "Our passion is to bring transformative CAR-T cell therapies to a broader group of patients by developing products that are efficacious and can be made widely available."
Joining fellow existing investor OrbiMed, Temasek Holdings, Lilly Asia Ventures and King Star Med . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.
Monthly subscriptions and discounted corporate plans for up to 100 members also available.